The BreastMed consortium will compare genetics of breast tumours at the clinical and molecular levels between 2 european and 3 mediterranean countries,considering different risk factors and clinical presentation heterogeneities. Germline BRCA1 and BRCA2 mutations will be sought, and molecular profiles of gene expression of a limited number of selected genes will be analysed in breast tumours by low-density cDNA chips. In 3 years, 750 tumours or patients (and their family if hereditary predisposition is suspected), will be recruited for the study. Better genetic counselling to breast cancer risk families, medical cares adaptated to the diagnosis of hereditary breast cancer risk or expression profiles of sporadic breast tumours, and standards for DNA chips manufacturing and comparisons are the main expected results of the consortium.
Funding SchemeCSC - Cost-sharing contracts
5000 Namur / Namen
10100 Rabat / Agdal
1107 2180 Beirut